Insider Selling: USANA Health Sciences, Inc. (USNA) Insider Sells $345,060.00 in Stock
USANA Health Sciences, Inc. (NYSE:USNA) insider Daniel A. Macuga sold 5,751 shares of the firm’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $60.00, for a total transaction of $345,060.00. Following the transaction, the insider now directly owns 2,077 shares of the company’s stock, valued at approximately $124,620. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
USANA Health Sciences, Inc. (NYSE:USNA) opened at 59.20 on Friday. The company’s 50-day moving average is $59.06 and its 200-day moving average is $60.22. The company has a market cap of $1.45 billion, a P/E ratio of 15.38 and a beta of 1.10. USANA Health Sciences, Inc. has a 52 week low of $52.55 and a 52 week high of $75.00.
USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $0.98 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.08. The business had revenue of $257.10 million during the quarter, compared to analysts’ expectations of $273.61 million. USANA Health Sciences had a net margin of 9.47% and a return on equity of 28.93%. USANA Health Sciences’s revenue for the quarter was down .5% on a year-over-year basis. During the same period last year, the company posted $2.07 EPS. On average, analysts anticipate that USANA Health Sciences, Inc. will post $3.79 EPS for the current fiscal year.
USANA Health Sciences announced that its Board of Directors has authorized a stock buyback plan on Tuesday, July 25th that permits the company to buyback $64.60 million in shares. This buyback authorization permits the company to buy up to 46% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its stock is undervalued.
A number of brokerages recently weighed in on USNA. BidaskClub downgraded shares of USANA Health Sciences from a “sell” rating to a “strong sell” rating in a research note on Monday, July 31st. Pivotal Research lowered their target price on shares of USANA Health Sciences from $75.00 to $70.00 and set a “buy” rating for the company in a research note on Wednesday, July 26th.
A number of large investors have recently made changes to their positions in the stock. American International Group Inc. boosted its stake in shares of USANA Health Sciences by 7.1% in the first quarter. American International Group Inc. now owns 6,392 shares of the company’s stock valued at $368,000 after buying an additional 422 shares during the last quarter. Prudential Financial Inc. boosted its stake in shares of USANA Health Sciences by 22.4% in the first quarter. Prudential Financial Inc. now owns 69,763 shares of the company’s stock valued at $4,019,000 after buying an additional 12,757 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of USANA Health Sciences during the first quarter valued at $515,000. JPMorgan Chase & Co. boosted its stake in shares of USANA Health Sciences by 1.2% in the first quarter. JPMorgan Chase & Co. now owns 16,044 shares of the company’s stock valued at $924,000 after buying an additional 196 shares during the last quarter. Finally, MARSHALL WACE ASIA Ltd purchased a new stake in shares of USANA Health Sciences during the first quarter valued at $1,436,000. 44.73% of the stock is owned by institutional investors and hedge funds.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.